Abstract
With the introduction of several new antiplatelet and anticoagulant agents that have multiple actions and interactions, selection of the optimal antithrombotic has become quite complex. This article discusses direct Xa inhibitors, direct thrombin inhibitors, GP IIb/IIIa inhibitors, adenosine diphosphate inhibitors, as well as novel targets for antithrombotic therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have